Context Therapeutics Financials - Benzinga

Context Therapeutics Inc

CNTXNASDAQ

Trade with Public

Trade with Public

$0.5229

0.01653.26%

At close: Aug 14, 5:00 PM EST

$0.5250

0.00210.4%

After Hours: Aug 14, 7:25 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Context Therapeutics Financials

Context Therapeutics (CNTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move

Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.

Tanya Rawat

PRO
Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 66.67 percent decrease over losses of $(0.09) per

Benzinga Newsdesk

PRO
Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of $(0.05) per share from

Benzinga Newsdesk

PRO
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.

Benzinga Newsdesk

PRO
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses of $(0.22) per share

Benzinga Newsdesk

PRO
Context Therapeutics Q2 EPS $(0.09) Misses $(0.06) Estimate, Cash And Cash Equivalents Were $83.5M Expected To Be Sufficient To Fund Its Operations Into 2027

Benzinga Newsdesk